{"transactions":[{"id":765981,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":44738,"kind":"person","name":"Lawton Alison Frances","position":1,"cik":"0001542650","reported_name":"Lawton Alison Frances","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-22T20:30:09.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":6090,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":6090,"derivative":{"exercise_price":89.63,"expiration_date":"2036-05-21","underlying":"Common Stock","underlying_shares":6090},"source":{"system":"sec-edgar","filing":"0001542650-26-000002","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000154265026000002/ownership.xml","form_type":"4"}},{"id":1137206,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":44738,"kind":"person","name":"Lawton Alison Frances","position":1,"cik":"0001542650","reported_name":"Lawton Alison Frances","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-22T20:41:04.000Z","date":"2025-05-22","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":12500,"derivative":{"exercise_price":18.36,"expiration_date":"2035-05-22","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0000950170-25-076403","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000095017025076403/ownership.xml","form_type":"4"}},{"id":1483089,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":44738,"kind":"person","name":"Lawton Alison Frances","position":1,"cik":"0001542650","reported_name":"Lawton Alison Frances","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-11T20:12:24.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer."}],"balance_after":96667,"source":{"system":"sec-edgar","filing":"0001628280-24-027672","document":"wk-form4_1718136736.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024027672/wk-form4_1718136736.xml","form_type":"4"}},{"id":1500435,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":44738,"kind":"person","name":"Lawton Alison Frances","position":1,"cik":"0001542650","reported_name":"Lawton Alison Frances","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-28T23:58:11.000Z","date":"2024-05-23","kind":"grant","planned":false,"acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":11000,"derivative":{"exercise_price":21.77,"expiration_date":"2034-05-22","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0000950170-24-065540","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000095017024065540/ownership.xml","form_type":"4"}},{"id":1782079,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":44738,"kind":"person","name":"Lawton Alison Frances","position":1,"cik":"0001542650","reported_name":"Lawton Alison Frances","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-14T01:17:43.000Z","date":"2023-09-11","kind":"grant","planned":false,"acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 6,500 shares of the Issuer's common stock, which will vest in full on the date that is the earlier of (i) the Issuer's 2024 Annual Meeting of Stockholders and (ii) September 11, 2024, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":6500,"derivative":{"exercise_price":11.2,"expiration_date":"2033-09-10","underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0000899243-23-018867","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000089924323018867/doc4.xml","form_type":"4"}},{"id":1840840,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":44738,"kind":"person","name":"Lawton Alison Frances","position":1,"cik":"0001542650","reported_name":"Lawton Alison Frances","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-30T20:30:12.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":1950000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This option award is contingent upon receiving stockholder approval of the amendment and/or restatement of the 2016 Equity Incentive Plan to increase the number of shares available for issuance thereunder."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 22, 2023, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":1950000,"derivative":{"exercise_price":0.3,"expiration_date":"2033-06-22","underlying":"Common Stock","underlying_shares":1950000},"source":{"system":"sec-edgar","filing":"0001209191-23-040328","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1542650/000120919123040328/doc4.xml","form_type":"4"}},{"id":1855579,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":44738,"kind":"person","name":"Lawton Alison Frances","position":1,"cik":"0001542650","reported_name":"Lawton Alison Frances","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-14T20:51:21.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (?RSUs?) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer?s next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer."}],"balance_after":51667,"source":{"system":"sec-edgar","filing":"0001628280-23-022084","document":"wk-form4_1686775872.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023022084/wk-form4_1686775872.xml","form_type":"4"}},{"id":2218699,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":44738,"kind":"person","name":"Lawton Alison Frances","position":1,"cik":"0001542650","reported_name":"Lawton Alison Frances","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-30T22:36:13.000Z","date":"2022-06-28","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in full upon the earlier to occur of (a) June 28, 2023 or (b) the next annual meeting of the Issuer's stockholders."}],"balance_after":20000,"derivative":{"exercise_price":1.21,"expiration_date":"2032-06-27","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-22-024675","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000089924322024675/doc4.xml","form_type":"4"}},{"id":2220965,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":44738,"kind":"person","name":"Lawton Alison Frances","position":1,"cik":"0001542650","reported_name":"Lawton Alison Frances","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-27T20:17:19.000Z","date":"2022-06-06","kind":"grant","acquired":true,"shares":6667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an annual grant of restricted stock units (\"RSUs\") for service as a director to the Issuer. The RSUs will vest in two equal annual installments on June 6, 2023 and June 6, 2024, subject to the Reporting Person continuing to provide service to the Issuer through the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents unvested RSUs."}],"balance_after":6667,"source":{"system":"sec-edgar","filing":"0001628280-22-018054","document":"wf-form4_165636101128022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828022018054/wf-form4_165636101128022.xml","form_type":"4"}},{"id":2235470,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":44738,"kind":"person","name":"Lawton Alison Frances","position":1,"cik":"0001542650","reported_name":"Lawton Alison Frances","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2022-06-10T10:04:15.000Z","date":"2022-06-07","kind":"grant","acquired":true,"shares":43000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 7, 2022, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":43000,"derivative":{"exercise_price":0.73,"expiration_date":"2032-06-06","underlying":"Common Stock","underlying_shares":43000},"source":{"system":"sec-edgar","filing":"0001209191-22-035691","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1542650/000120919122035691/doc4.xml","form_type":"4"}},{"id":2675102,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":44738,"kind":"person","name":"Lawton Alison Frances","position":1,"cik":"0001542650","reported_name":"Lawton Alison Frances","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2021-06-09T21:24:47.000Z","date":"2021-06-08","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 8, 2021, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":40000,"derivative":{"exercise_price":6.8,"expiration_date":"2031-06-07","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-21-039228","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1542650/000120919121039228/doc4.xml","form_type":"4"}},{"id":2683366,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":44738,"kind":"person","name":"Lawton Alison Frances","position":1,"cik":"0001542650","reported_name":"Lawton Alison Frances","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-03T22:36:04.000Z","date":"2021-06-01","kind":"grant","acquired":true,"shares":18188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in full upon the earlier to occur of (a) June 1, 2022 or (b) the next annual meeting of the Issuer's stockholders."}],"balance_after":18188,"derivative":{"exercise_price":12.91,"expiration_date":"2031-05-31","underlying":"Common Stock","underlying_shares":18188},"source":{"system":"sec-edgar","filing":"0000899243-21-021848","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000089924321021848/doc4.xml","form_type":"4"}},{"id":2685949,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":44738,"kind":"person","name":"Lawton Alison Frances","position":1,"cik":"0001542650","reported_name":"Lawton Alison Frances","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-02T21:02:57.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":6000,"price":9.5,"value":57000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"8.3333% of the shares subject to the option shall vest on July 2, 2021, with the remainder vesting in equal monthly installments of 8.333% of the shares subject to the option until the 12-month anniversary of the date of the grant (or, if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant) subject to the Reporting Person continuing to provide services through each such date."}],"balance_after":6000,"derivative":{"exercise_price":9.5,"expiration_date":"2031-06-02","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001628280-21-011543","document":"wf-form4_162266774296212.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828021011543/wf-form4_162266774296212.xml","form_type":"4"}},{"id":2933057,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":44738,"kind":"person","name":"Lawton Alison Frances","position":1,"cik":"0001542650","reported_name":"Lawton Alison Frances","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-24T00:13:26.000Z","date":"2020-12-22","kind":"grant","acquired":true,"shares":36377,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable over three years, with 33% of this option vesting on December 22, 2021, and the remainder vesting in 24 equal monthly installments thereafter."}],"balance_after":36377,"derivative":{"exercise_price":7.85,"expiration_date":"2030-12-21","underlying":"Common Stock","underlying_shares":36377},"source":{"system":"sec-edgar","filing":"0000899243-20-035052","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000089924320035052/doc4.xml","form_type":"4"}},{"id":2939421,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":44738,"kind":"person","name":"Lawton Alison Frances","position":1,"cik":"0001542650","reported_name":"Lawton Alison Frances","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-12-17T21:33:39.000Z","date":"2020-12-15","kind":"grant","acquired":true,"shares":47200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 36 equal monthly installments beginning on January 15, 2021 until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":47200,"derivative":{"exercise_price":9.09,"expiration_date":"2030-12-14","underlying":"Common Stock","underlying_shares":47200},"source":{"system":"sec-edgar","filing":"0001209191-20-064066","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1542650/000120919120064066/doc4.xml","form_type":"4"}},{"id":3011493,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":44738,"kind":"person","name":"Lawton Alison Frances","position":1,"cik":"0001542650","reported_name":"Lawton Alison Frances","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-10-06T11:43:06.000Z","date":"2020-10-05","kind":"grant","acquired":true,"shares":6854,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"33.3333% of the shares subject to the option shall vest on October 5, 2021, with the remainder vesting thereafter in equal monthly installments of 2.7777% of the shares subject to the option until the 36-month anniversary of the date of the grant, subject to the Reporting Person's continued services as a director through each applicable vesting date."}],"balance_after":6854,"derivative":{"exercise_price":7.33,"expiration_date":"2030-10-04","underlying":"Common Stock","underlying_shares":6854},"source":{"system":"sec-edgar","filing":"0001628280-20-014324","document":"wf-form4_160198457295532.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828020014324/wf-form4_160198457295532.xml","form_type":"4"}},{"id":3174276,"issuer":{"id":129745,"kind":"organization","name":"Kaleido Biosciences, Inc.","symbol":"KLDO"},"owners":[{"id":44738,"kind":"person","name":"Lawton Alison Frances","position":1,"cik":"0001542650","reported_name":"Lawton Alison Frances","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-17T08:00:46.000Z","date":"2020-04-15","kind":"grant","acquired":true,"shares":118500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest on April 15, 2021, with the remaining 75% vesting in 12 equal quarterly installments thereafter."}],"balance_after":118500,"derivative":{"exercise_price":6,"expiration_date":"2030-04-14","underlying":"Common Stock","underlying_shares":118500},"source":{"system":"sec-edgar","filing":"0000899243-20-010884","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1751299/000089924320010884/doc4.xml","form_type":"4"}},{"id":3233249,"issuer":{"id":129745,"kind":"organization","name":"Kaleido Biosciences, Inc.","symbol":"KLDO"},"owners":[{"id":44738,"kind":"person","name":"Lawton Alison Frances","position":1,"cik":"0001542650","reported_name":"Lawton Alison Frances","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2020-03-03T21:07:08.000Z","date":"2020-02-28","kind":"grant","acquired":true,"shares":46325,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units shall vest 100% on February 28, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units shall vest 100% on February 28, 2022."}],"balance_after":46325,"derivative":{"underlying":"Common Stock","underlying_shares":46325},"source":{"system":"sec-edgar","filing":"0000899243-20-006859","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1751299/000089924320006859/doc4.xml","form_type":"4"}},{"id":3368609,"issuer":{"id":129745,"kind":"organization","name":"Kaleido Biosciences, Inc.","symbol":"KLDO"},"owners":[{"id":44738,"kind":"person","name":"Lawton Alison Frances","position":1,"cik":"0001542650","reported_name":"Lawton Alison Frances","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-11-18T16:05:40.000Z","date":"2019-11-15","kind":"grant","acquired":false,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest on November 15, 2020, with the remaining 75% vesting in equal quarterly installments over the next three years."}],"balance_after":150000,"derivative":{"exercise_price":6.56,"expiration_date":"2029-11-14","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0000899243-19-027503","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1751299/000089924319027503/doc4.xml","form_type":"4"}},{"id":3478541,"issuer":{"id":5242,"kind":"organization","name":"Verastem, Inc.","symbol":"VSTM"},"owners":[{"id":44738,"kind":"person","name":"Lawton Alison Frances","position":1,"cik":"0001542650","reported_name":"Lawton Alison Frances","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-26T01:40:07.000Z","date":"2019-06-21","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal monthly installments (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which the remaining unvested portion shall vest), beginning on 7/21/2019 and ending on 06/21/2020, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":1.81,"expiration_date":"2029-06-21","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-19-037502","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1526119/000110465919037502/a4.xml","form_type":"4"}},{"id":3619615,"issuer":{"id":129745,"kind":"organization","name":"Kaleido Biosciences, Inc.","symbol":"KLDO"},"owners":[{"id":44738,"kind":"person","name":"Lawton Alison Frances","position":1,"cik":"0001542650","reported_name":"Lawton Alison Frances","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-03-04T20:12:09.000Z","date":"2019-03-04","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest on January 23, 2020, with the remainder vesting in 12 equal quarterly installments thereafter."}],"balance_after":150000,"derivative":{"exercise_price":15,"expiration_date":"2029-03-04","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0000899243-19-005960","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1751299/000089924319005960/doc4.xml","form_type":"4"}},{"id":3659838,"issuer":{"id":5242,"kind":"organization","name":"Verastem, Inc.","symbol":"VSTM"},"owners":[{"id":44738,"kind":"person","name":"Lawton Alison Frances","position":1,"cik":"0001542650","reported_name":"Lawton Alison Frances","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-13T21:53:06.000Z","date":"2018-06-11","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal monthly installments (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which the remaining unvested portion shall vest), beginning on 7/11/2018 and ending on 06/11/2019, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":5.59,"expiration_date":"2028-06-11","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000904454-19-000225","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1526119/000090445419000225/edgar.xml","form_type":"5"}},{"id":4280382,"issuer":{"id":5242,"kind":"organization","name":"Verastem, Inc.","symbol":"VSTM"},"owners":[{"id":44738,"kind":"person","name":"Lawton Alison Frances","position":1,"cik":"0001542650","reported_name":"Lawton Alison Frances","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-15T20:23:51.000Z","date":"2017-06-13","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in twelve monthly installments through June 13, 2018, with the first monthly installment vesting on July 13, 2017."}],"balance_after":25000,"derivative":{"exercise_price":2.09,"expiration_date":"2027-06-13","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-17-039562","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1526119/000110465917039562/a4.xml","form_type":"4"}},{"id":4413442,"issuer":{"id":12304,"kind":"organization","name":"CoLucid Pharmaceuticals, Inc.","symbol":"CLCD"},"owners":[{"id":44738,"kind":"person","name":"Lawton Alison Frances","position":1,"cik":"0001542650","reported_name":"Lawton Alison Frances","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-03-01T12:16:30.000Z","date":"2017-03-01","kind":"disposition_to_issuer","acquired":false,"shares":658,"price":10.3,"value":6777.4,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the \"Merger Agreement\"), by and among CoLucid Pharmaceuticals, Inc. (the \"Issuer\"), Eli Lilly and Company (\"Lilly\") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest."}],"balance_after":0,"derivative":{"exercise_price":36.2,"expiration_date":"2027-01-03","underlying":"Common Stock","underlying_shares":658},"source":{"system":"sec-edgar","filing":"0000911916-17-000074","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1348649/000091191617000074/edgar.xml","form_type":"4"}},{"id":4413441,"issuer":{"id":12304,"kind":"organization","name":"CoLucid Pharmaceuticals, Inc.","symbol":"CLCD"},"owners":[{"id":44738,"kind":"person","name":"Lawton Alison Frances","position":1,"cik":"0001542650","reported_name":"Lawton Alison Frances","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-03-01T12:16:30.000Z","date":"2017-03-01","kind":"disposition_to_issuer","acquired":false,"shares":8897,"price":40.26,"value":358193.22,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, these options, which provided for full vesting immediately prior to the start of the Issuer's first annual meeting of stockholders following the date of grant, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest."}],"balance_after":0,"derivative":{"exercise_price":6.24,"expiration_date":"2026-05-10","underlying":"Common Stock","underlying_shares":8897},"source":{"system":"sec-edgar","filing":"0000911916-17-000074","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1348649/000091191617000074/edgar.xml","form_type":"4"}},{"id":4413440,"issuer":{"id":12304,"kind":"organization","name":"CoLucid Pharmaceuticals, Inc.","symbol":"CLCD"},"owners":[{"id":44738,"kind":"person","name":"Lawton Alison Frances","position":1,"cik":"0001542650","reported_name":"Lawton Alison Frances","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-03-01T12:16:30.000Z","date":"2017-03-01","kind":"disposition_to_issuer","acquired":false,"shares":1420,"price":39.96,"value":56743.2,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the \"Merger Agreement\"), by and among CoLucid Pharmaceuticals, Inc. (the \"Issuer\"), Eli Lilly and Company (\"Lilly\") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest."}],"balance_after":0,"derivative":{"exercise_price":6.54,"expiration_date":"2026-03-11","underlying":"Common Stock","underlying_shares":1420},"source":{"system":"sec-edgar","filing":"0000911916-17-000074","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1348649/000091191617000074/edgar.xml","form_type":"4"}},{"id":4501811,"issuer":{"id":12304,"kind":"organization","name":"CoLucid Pharmaceuticals, Inc.","symbol":"CLCD"},"owners":[{"id":44738,"kind":"person","name":"Lawton Alison Frances","position":1,"cik":"0001542650","reported_name":"Lawton Alison Frances","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-01-04T16:19:22.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":658,"price":30.4,"value":20003.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This option was issued to the reporting person pursuant to the CoLucid Pharmaceuticals, Inc. Non-Employee Director Compensation Policy in lieu of cash compensation of $20,000."}],"balance_after":658,"derivative":{"exercise_price":36.2,"exercise_date":"2017-01-03","expiration_date":"2027-01-03","underlying":"Common Stock","underlying_shares":658},"source":{"system":"sec-edgar","filing":"0000911916-17-000020","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1348649/000091191617000020/edgar.xml","form_type":"4"}}]}